Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Rex Eupseiphos, I normally run the same statist

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154887
(Total Views: 850)
Posted On: 05/23/2020 4:48:22 PM
Avatar
Posted By: TechGuru
Re: Rex Eupseiphos #35161
Rex Eupseiphos,

I normally run the same statistical analysis that FDA will do with the data to try and make an idea of where I stand with my investment (and re-allocate accordingly).

At the end of the day, we can talk all day long, but if we do not demonstrate significance (p<0.05) we are toasted and FDA will not approve .

So, in the case of Severe or Critical, the primary end point is survival:

Quote:
Primary Outcome Measures :
All-cause mortality at Day 28



The Montefiore patients where perhaps beyond critical (worse) but, lets assume they where in the trial "normal" population. We know that there have been reported deaths of 88% for this cohort.

https://pubmed.ncbi.nlm.nih.gov/32320003/


The question is: How many need to survive for statistical significance ?? Using a two-tailed test and binomial distribution we obtain that 4 patients survival will yield a p-number of p=0.0239 5 patients 0.00371 and 6 patients 0.000406

So, I will say we obtained statistical significance with the Montefiore patients as per Dr. Patterson paper (if more than 4 are alive at day 28)

Now, if we take the Southern California cohort the (31/32) number is even better (to put it mildly), however not sure if all of them where in the Severe or Critical condition, so I prefer not to run any numbers with this cohort, but, let me just say, if they where mild to moderate, we would crush the p-number (to use NP words) just the same as if they where Severe to Critical.

Any way you slice it we are good. Let's hope the trial shows the same response as the results reported so far.


(8)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us